SHANGHAI, China and ROCKVILLE, MD., April 29, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet

SHANGHAI, China, and ROCKVILLE, Md., and MUNICH, Germany, April 27, 2020 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant

SHANGHAI, China and ROCKVILLE, MD., April 24, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet

SHANGHAI, China, and ROCKVILLE, MD., April 06, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet

SHANGHAI, China and ROCKVILLE, MD., April 03, 2020 (GLOBE NEWSWIRE) -- I-Mab (Nasdaq: IMAB) ( the “Company”), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet

- The clinical study will evaluate the safety and preliminary efficacy of TJC4, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - Initiation of development of TJC4 in China follows an ongoing Phase 1 study in U.S.

Successfully completed initial public offering raising approximately $114.5 million in gross proceeds Continued execution across broad pipeline portfolio; multiple clinical data readouts expected in 2020 Company to host conference call and webcast, March 31 at 8:00 a.m.

-The clinical study will explore the potential of TJM2, an anti-GM-CSF monoclonal antibody, to treat cytokine release syndrome in severe and critically ill patients with coronavirus disease -Submission follows the announcement of plans to develop TJM2 in the U.S.

- Kalbe Genexine Biologics (“KG Bio”) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mab’s TJD5, in Southeast Asia and other territories - Partnership to include right of first negotiation on an additional I-Mab-discovered product candidate to be

Fernando J. Sallés, Ph.D., CLP ® , Appointed to Lead I-Mab’s U.S. and EU Business Development SHANGHAI, China and ROCKVILLE, MD., March 27, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and